



SCYNE^oXIS

**A dynamic force in
the fight against
infectious disease**

January 2024

Forward-Looking Statement

Certain statements regarding SCYNEXIS, Inc. (the “Company”) made in this presentation constitute forward-looking statements, including, but not limited to, statements regarding our business strategies and goals, plans and prospects, market size, adoption rate, potential revenue, clinical validity and utility, growth opportunities, future products and product pipeline. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our expectations. These risks and uncertainties include, but are not limited, to: BREXAFEMME may not be accepted by physicians and patients at the rate SCYNEXIS expects; risks inherent in SCYNEXIS’ ability to successfully develop and obtain FDA approval for ibrexafungerp for additional indications; unexpected delays may occur in the timing of acceptance by the FDA of an NDA submission; the expected costs of commercializing BREXAFEMME or of clinical studies and when they might begin or be concluded; SCYNEXIS’ need for additional capital resources; and SCYNEXIS’ reliance on third parties to conduct SCYNEXIS’ clinical studies and commercialize its products. The use of words such as “anticipates,” “expects,” “intends,” “plans,” “could,” “should,” “would,” “may,” “will,” “believes,” “estimates,” “potential,” or “continue” and variations or similar expressions are intended to identify forward-looking statements, but not all forward-looking statements may be so identified. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in the Company’s most recent reports filed with the Securities and Exchange Commission (“SEC”), including under the caption “Risk Factors” in the Company’s annual report on Form 10-K for the year ended December 31, 2022, and in the Company’s subsequent quarterly reports on Form 10-Q, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. The Company undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this presentation, or to reflect actual outcomes.

Scynexis Corporate Update – January 2024



GSK Amended Agreement Including Path Forward for Restart of the MARIO Study

Total potential deal value of \$448 million plus royalties. \$115 million already received.



SCY-247 Update

New promising pre-clinical data to be presented at the 11th Advances Against Aspergillosis and Mucormycosis (AAAM) Conference in Milan, Italy January 25 – 27, 2024

Phase 1 study initiation planned for 2024



FURI / CARES / SCYNERGIA / VANQUISH / NATURE Studies Update

Enrollment completed, analysis ongoing, on target for study reports in 1H 2024




Strong Balance Sheet

Cash runway > 2 years (\$105 million in cash and cash investments as of 9/30/2023)

Limited Antifungal Development Coupled With Escalating Resistance Has Resulted in Substantial Public Health Burden

SCYNEXIS aims to address antimicrobial resistance (AMR) by bringing a ground-breaking class of drugs with the strength, safety and versatility to defeat even the most insidious fungal diseases



Fungal Resistance a Growing, Global, Public Health Threat

Antifungal development is a well-recognized priority


WHO Releases First-Ever List of Priority Deadly Fungal Pathogens



W.H.O. Lists Top Fungal Health Threats

The pathogens cause infections that kill millions of people each year and often go undiagnosed. Even when identified, a growing number of infections is resistant to the current crop of drugs.

Give this article



Cultured *Candida auris*, right, and cultured *Candida albicans*. Centers for Disease Control and Prevention

WHO fungal priority pathogens list to guide research, development and public health action



Fungal Outbreaks Increasing

Deadly fungal infection spreading at an alarming rate, CDC says

The fungus, a type of yeast called *Candida auris*, or *C. auris*, can cause severe illness in people with weakened immune systems.

HEALTH

The potentially deadly *Candida auris* fungus is spreading quickly in the U.S.

March 21, 2023 · 2:12 AM ET

CDC Identifies Drug Resistant *Candida* spp. and *C. auris* as Serious and Urgent Threats

DRUG-RESISTANT
CANDIDA AURIS
THREAT LEVEL URGENT


BARDA New Priority: Antifungals

New Priority: Advanced Development of Antifungals

Estimated number of US hospitalizations due to fungal infections is ~75,000/year

Resistance to existing antifungal drugs is on the rise

Secondary & opportunistic invasive fungal infections pose a significant health threat following a mass casualty incident (e.g., Rad/Nuc event, respiratory pandemic)



Prioritize investment towards new classes, broad spectrum, oral/IV

Candida species, including *Candida auris*, & *Aspergillus* species

Rare molds, such as *Mucorales*, also of interest

NOVEMBER 15-16
VIRTUAL EVENT | W


See updated BAA Area of Interest 3.2 and request a TechWatch Meeting



Bio.News
Everything biotech

PASTEUR Act reintroduced in House, Senate

April 28, 2023 / Bio's View, Federal Policy, Health, Latest News / By BioNews Staff



Fungerpis are Well-Suited to Address High Priority Fungal Pathogens

 Demonstrated activity vs. fungi in both critical and high priority WHO Fungal Priority Pathogens list¹



SCY-247 (IV and oral):
 Significant opportunity based on broad spectrum activity and fungerpis-like tolerability

Ibrexafungerpis:
 GSK estimated opportunity as >\$500M based on broad coverage of key pathogens²

	Fungerpis	Echinocandin	Azole	Polyene
Companies	  (SCY-247) (Ibrexafungerpis)	  	  	  
Peak Sales per Product	> \$500M (potential) ²	~\$370M to \$680M ³	~\$720M to >\$1B ³	~\$500M ³


1. www.who.int/news/item/25-10-2022-who-releases-first-ever-list-of-health-threatening-fungi

2. GSK press briefing on SCYNE XIS/BREXAFEMME March 30, 2023

3. Based on company filings and Symphony data (US)

Opportunities to Grow Shareholder Value


Advancing proprietary platform of triterpenoid fungicidal while evaluating next generation innovations



Maximize **Ibrexafungerp** opportunity

Partnership with **GSK** optimizes BREXAFEMME commercial potential in VVC and RVVC

SCYX continued execution of development activities to ensure full value potential is realized



Advance **next generation** fungicidal

SCY-247 in invasive fungal infections with critical needs


Leverages core internal expertise

Addresses recognized unmet needs with significant market potential

Strengthened balance sheet enhances the opportunity to deliver **additional innovative therapies** to patients with significant unmet need


Ibexafungerp GSK Licensing Agreement following December 2023 Amendment

Total deal value of \$448 million plus royalties (revised from \$593 million)



Fungerp Pipeline

A New Class of Antifungals – Powerful - Different



**SCY-247:
Next Generation Fungerp**



SCY-247 – Our Next Generation Fungerp

Scientific Meeting Data

11th Congress on Trends in Medical Mycology (TIMM) - October 2023

- Potent and broad-spectrum *in vitro* activity, including against a large array of yeasts, molds and dimorphic fungi
- Extensive tissue distribution in animal models
- Fungicidal activity against multi-drug resistant strains, including *Candida albicans* and *Candida auris*
- *In vivo* efficacy in a mouse model of invasive candidiasis

11th Advances Against Aspergillosis and Mucormycosis (AAAM) Conference – to be Presented in January 2024

- *In vivo* efficacy in treating a Mucorales pulmonary infection in immunosuppressed mice
 - Efficacy of SCY-247 was equivalent to antifungals currently used to treat mucormycosis
 - The combination of SCY-247 with liposomal amphotericin B resulted in a statistically significant survival improvement when compared to either monotherapy

SCY-247 – In Development Against Resistant Fungal Infections



Anticipated Qualified Infectious Disease Product (QIDP) designation, Orphan Drug Designation and Fast Track (regulatory exclusivity of at least 10 years)




IP wholly owned by SCYNEXIS



Development backed by NIH

NIH provided ~\$3M funding to Case Western University for development of SCY-247 against *C. auris*



IND-enabling studies in progress

Phase 1 study initiation anticipated in 2024

SCYNEXIS Strongly Positioned for Value Creation



Category leader in the fight against deadly fungal pathogens with new antifungal (SCY-247) in development



Global urgency to rapidly develop potent antifungals to treat emerging infectious threats



Demonstrated internal expertise, solid supply chain and long IP protection, and potential for next generation products and partnerships



Strong Balance Sheet with cash runway of more than 2 years